You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 13, 2025

Mechanism of Action: Endothelin Receptor Antagonists


✉ Email this page to a colleague

« Back to Dashboard


Drugs with Mechanism of Action: Endothelin Receptor Antagonists

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm AMBRISENTAN ambrisentan TABLET;ORAL 210784-002 Mar 28, 2019 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Watson Labs Inc AMBRISENTAN ambrisentan TABLET;ORAL 208252-002 Mar 28, 2019 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Aurobindo Pharma AMBRISENTAN ambrisentan TABLET;ORAL 216531-001 Jul 21, 2022 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Endothelin Receptor Antagonists Market Analysis and Financial Projection

The endothelin receptor antagonists (ERAs) market is experiencing dynamic growth driven by increasing prevalence of chronic diseases and strategic pharmaceutical developments, while navigating a complex patent landscape with impending expirations and evolving regulatory policies.

Market Dynamics

Growth Drivers

  • Rising Disease Burden: ERAs are critical in treating pulmonary arterial hypertension (PAH), with a global market projected to reach USD 5.58 billion by 2032 (6% CAGR from 2024)[1][9]. Hypertension prevalence (e.g., 30% in Indian adults, 103 million cases in the U.S.) fuels demand[1].
  • Strategic Corporate Moves: Mergers (e.g., Viatris Inc. from Mylan and Pfizer’s Upjohn)[1] and product launches (e.g., generics for PAH) enhance market penetration.
  • Healthcare Investment: Government initiatives and increased spending, particularly in Asia-Pacific, support infrastructure and affordability[1][9].

Market Segmentation

  • Drugs: Ambrisentan, bosentan, and macitentan dominate[1][12].
  • Indications: Cardiovascular diseases (primary use), scleroderma, and emerging oncology applications[1][2][10].
  • Regions: North America leads due to advanced diagnostics[1], while Asia-Pacific grows via generics and economic development[1][12].

Challenges

  • High Treatment Costs: ERA therapies remain expensive, limiting accessibility[1].
  • Patent Expirations: Key patents (e.g., bosentan, macitentan) expire between 2025 and 2031, opening doors for generics[5][13].

Patent Landscape

Key Patents and Expirations

Patent Number Title Expiration Status
US7094781 Sulfamides as ERAs Dec 2025 Active
US8268847 Therapeutic compositions (e.g., Opsynvi) Apr 2029 Active
US10946015 Stable formulations Sep 2026 Active
  • Opsynvi: Protected until 2031 via orphan drug exclusivity[5]. Patents in the U.S., Australia, and Hungary have extensions, delaying generics[13].
  • Geographic Variations: Luxembourg and Norway markets already have generic entry due to expired patents[13].

Pipeline and Innovation

  • Late-Stage Candidates:
    • Zibotentan (AstraZeneca): Phase III for prostate cancer[6][10].
    • SC0062 (Biocity Biopharmaceutics): Phase II for diabetic kidney disease[6].
  • Novel Targets: Research spans glaucoma, retinopathy, and kidney diseases using selective ET-A/B antagonists[8][15].

Competitive Landscape

  • Major Players: Johnson & Johnson, GSK, Idorsia, and AstraZeneca lead in ERA development[4][14].
  • R&D Focus: Small molecules (75% of pipeline) and combination therapies dominate[6][14].

Regulatory and Legal Trends

  • USPTO Fee Changes: From October 2024, surcharges for continuation applications (e.g., +$2,200 after 5 years) may accelerate patent filings[16].
  • Litigation Risks: Polymorph and formulation patents (e.g., Actelion’s macitentan) face challenges from generics[13].

Future Outlook

  • Generic Competition: Macitentan generics expected post-2031, with Teva and Sandoz poised for entry[13].
  • Therapeutic Expansion: ERAs are being tested in oncology (e.g., CRPC)[10] and ocular diseases (e.g., glaucoma)[15], broadening applications.

"The ERA market is a nexus of innovation and accessibility, balancing patent-driven exclusivity with unmet medical needs." – Industry Report[1][9].

Key Takeaways

  1. The ERA market will grow steadily (6% CAGR) driven by PAH and chronic diseases.
  2. Patent expirations post-2025 will reshape competition, favoring generics in Asia-Pacific and niche markets.
  3. Pipeline diversity (oncology, ophthalmology) and regulatory strategies (e.g., orphan designations) are critical for sustained growth.

FAQs

1. What are ERAs primarily used for?
ERAs treat pulmonary arterial hypertension and are being explored for cancer, kidney diseases, and glaucoma[1][2][15].

2. When will generic ERAs become widely available?
Key generics may enter post-2025, with macitentan expected by 2031[5][13].

3. How do USPTO fee changes impact ERA patents?
Higher fees for delayed filings could push companies to expedite applications or narrow claims[16].

4. Which companies dominate ERA development?
Johnson & Johnson, AstraZeneca, and Idorsia lead in pipeline innovation[4][6][14].

5. What challenges do ERA manufacturers face?
High costs, patent cliffs, and regulatory hurdles (e.g., complex litigation) are key barriers[1][13][16].

References

  1. https://www.databridgemarketresearch.com/reports/global-endothelin-antagonists-therapeutics-market
  2. https://pubchem.ncbi.nlm.nih.gov/patent/US-9125897-B2
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC7141375/
  4. https://synapse.patsnap.com/blog/what-are-endothelin-receptor-antagonists-and-how-do-you-quickly-get-the-latest-development-progress
  5. https://pharsight.greyb.com/drug/opsynvi-patent-expiration
  6. https://www.researchandmarkets.com/report/global-endothelin-receptor-antagonist-market
  7. https://patents.google.com/patent/US8071596B2/en
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC9965540/
  9. https://www.marketresearchintellect.com/product/endothelin-antagonists-therapeutics-market/
  10. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0133803
  11. https://www.drugpatentwatch.com/p/patent/7094781
  12. https://www.marketresearchintellect.com/product/global-endothelin-receptor-antagonist-market/
  13. https://www.greyb.com/wp-content/uploads/2016/08/Case-study-on-generic-pharma.pdf
  14. https://synapse.patsnap.com/blog/analysis-on-the-research-progress-of-endothelin-receptor-antagonist
  15. https://patents.justia.com/patent/20240189288
  16. https://www.jdsupra.com/legalnews/revolutionizing-the-patent-landscape-1786690/
  17. https://synapse.patsnap.com/target/81eb9d5f0768345ab5a04ae150296118
  18. https://allendyer.com/key-ip-legal-developments-to-watch-in-2025-ai-patents-and-court-reform/
Last updated: 2025-04-03

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.